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 1    Introduction 
Cancer significantly contributes to the worldwide burden of disease and premature death across many 
countries. Consequently, current oncology research focuses on discovering and validating new bi-
omarkers to improve early detection. These efforts are of worldwide importance in detecting significant 
cancer while it is still localised and in lessening associated morbidities and death.  
Biomarkers have mostly been sourced from non- or minimally invasive biofluids, such as blood, 
urine, and biopsy tissue. Traditionally, biomarkers were limited to circulating end-products of altered 
cellular function in cancer. However, technology advances and emergence of the –omics sciences have 
improved analysis of genes, gene expression, proteins and metabolites alike – on both an individual and 
system-wide scale. This field of research, termed “systems biology”, has allowed for molecules at all 
levels of the cellular hierarchy to be considered as biomarkers. Continuous improvements in sensitivity, 
resolution and precision of these analytical techniques produces large datasets, allowing for simultaneous 
characterisation of, ideally all, compounds in a single sample. Subsequent statistical analysis of these 
datasets and their interpretation with respect to cellular function is the basis of the different -omics tech-
nologies, such as genomics, transcriptomics, proteomics and metabolomics.  
In this chapter, we will describe principles and processes that are involved in investigating biolog-
ical or clinical problems with nuclear magnetic resonance (NMR)-based metabolomics - an approach that 
involves the global analysis of metabolites. In writing for the scope of this book, we have broken this 
chapter into three sections: (1) First we will describe and illustrate the methods commonly used in NMR-
based metabolomics, including spectral processing, data treatment and subsequent statistical analysis. (2) 
Secondly, we will use prostate cancer (PCa) as a case study to illustrate how NMR-based metabolomics 
can be applied to a clinical problem. PCa is the second most common type of cancer and the sixth leading 
cause of cancer-related death worldwide (Center et al., 2012; Ferlay et al., 2010; Siegel et al., 2012). The 
diagnosis of prostate cancer is currently problematic for a number of reasons that include lack of sensi-
tive and specific tumour markers as well as limitations due to morbidity inherent with the biopsy diagno-
sis process. Furthermore, many patients harbour early prostate cancer with insignificant tumours that may 
not progress to produce clinical problems. (3) Lastly, we will briefly outline the future directions for the 
role of NMR-based metabolomics, including personalized medicine and integration with other –omics 
datasets, in order to create a holistic, systems biology approach to solving clinical problems. 
Outlining the processes, applications and potential of metabolomics will be of assistance to bio-
statisticians and bioinformaticians who may be interested in expanding into this area of research. Similar-
ly, we aim to inspire scientists and clinicians who are interested in applying this approach to a scientific 
or clinical problem. 
2    Metabolomics: History and Methods 
2.1     What is Metabolomics? 
Metabolomics has been highlighted as a technique that is unique and exciting in biomarker discovery 
(Abate-Shen & Shen, 2009; Bino et al., 2004; Nicholson & Lindon, 2008). It is the quantification of all 
small molecular weight metabolites to accurately define the metabolite composition of a biological sam-
ple (Fiehn, 2002).   The term “metabolomics” is often used interchangeably with “metabonomics”, which 
 is defined as ‘the quantitative measurement of the dynamic multiparametric metabolic response of living 
systems to pathophysiological stimuli’ (Nicholson et al., 1999). The technical approach to both metabo-
nomics and metabolomics is similar, involving measurement and analysis of metabolite data for a given 
sample. Conceptually, however, the objective and application of these techniques is slightly different: 
Metabolomics seeks to describe the composition of complex biological samples, while metabonomics 
aims to map and understand the change of a biological system in response to external or artificial stimuli. 
In the current chapter, we will use the term “metabolomics”, while both metabolomics and metabonomics 
will be discussed. The advent and development of metabolomics/metabonomics has largely been possible 
due to advances in analytical techniques, such as nuclear magnetic resonance (NMR) spectroscopy and 
mass spectrometry (MS), as well as chromatographic separation techniques. As the authors have exper-
tise in NMR spectroscopy, the focus of this chapter will be on NMR-based techniques within the field of 
metabolomics. We refer the reader to several excellent reviews that detail the application of MS in 
metabolomics and systems biology (Lu et al., 2008; Pasikanti et al., 2008; Theodoridis et al., 2008) 
2.2     Historical Perspective 
While “metabolomics” is a recently coined term, the analysis of metabolic end products is a long-
practiced ancient scientific process. About 2000-1500 BCE, analysis of urine by human taste or animal 
behaviour (due to the high urinary glucose concentration) helped diagnose patients with diabetes mellitus 
(van der Greef & Smilde, 2005). In 1506, a “urine wheel” by Ulrich Pinder linked crude changes detected 
by human senses (colour, smell, taste) with various medical conditions (Pinder, 1506; Weiss & Kim, 
2012). Although qualitative measures of metabolism have been performed for centuries, the origins of 
quantitative studies stem from the measurement of insensible perspiration and other hydration losses in 
medieval Italy (Eknoyan, 1999). Technological limitations in analytical chemistry hindered further advances 
until the early 20th century. At this time, the development of sensitive analytical methods allowed quantifi-
cation of key compounds/metabolites in urine and other sample types (Simoni et al., 2002). This quanti-
tative approach continued to develop with the introduction of various analytical techniques, such as mass 
spectrometry (Griffiths, 2008; Thomson, 1912) and NMR (Bloch et al., 1946; Freeman, 1995; Purcell et 
al., 1946), and with the application of these techniques to metabolic research (Gates & Sweeley, 1978; 
Hoult et al., 1974). The integration of medical science and analytical chemistry at this time led to a great-
er understanding of metabolic perturbations in medical conditions, e.g. kidney stones among many others 
(Reginato & Kurnik, 1989). Further improvements in metabolite profiling in the latter half of the 20th 
century were aided by advances in chemometrics, the foundation behind data analysis in analytical chem-
istry (Geladi & Esbensen, 1990). Appropriate data processing and interpretation was achieved by multi-
variate statistical methods, which will be outlined in more detail below. 
2.3     Modern Metabolomics and its Varieties/Applications  
Metabolomics continues to evolve as a field and is increasingly used in a variety of applications. Initially, 
biofluids were analyzed specifically to quantify metabolic perturbations due to drug toxicity, disease, and 
other internal and external influences. For example, perturbations in steroid metabolism were used for 
anti-doping testing during the Los Angeles Summer Olympics in 1984 (Fitch, 2008). In the following 
section, the diverse applications of metabolomics are briefly described; more comprehensive accounts are 
available in other sources (Duarte & Gil, 2012; Ma et al., 2012b; Ng et al., 2011; Rhee & Gerszten, 
2012; Spratlin et al., 2009). 
 2.3.1     Biofluid and Excretion Analysis  
Metabolomics has been used to quantify endogenous metabolites in many human biofluids, with those 
most commonly analyzed being urine and blood (serum, plasma). Analysis of urine metabolites has 
shown early promise in diagnosing kidney (Ganti & Weiss, 2011) and bladder tumors (Hyndman et al., 
2011), as well as more systemic conditions such as type 2 diabetes mellitus (Salek et al., 2007). Indeed, 
distinct serum metabolite patterns have been characterized for abnormal clinical states including breast 
cancer (Oakman et al., 2011), leukemia (MacIntyre et al., 2010), sepsis and acute lung injury (Serkova et 
al., 2011), coronary artery disease (Brindle et al., 2002) and obesity (Oberbach et al., 2011; Xie et al., 
2012). Furthermore, cardiovascular health has been assessed by metabolomic analysis of feces, linking 
perturbations in the metabolite profiles of gut flora to the metabolic syndrome and dyslipidemia (Wang et 
al., 2011). Seminal fluid and expressed prostatic secretions (EPS), have been used to characterize dis-
turbed metabolism in prostate cancer (Averna et al., 2005; Kline et al., 2006; Lynch et al., 1994, 1997; 
Serkova et al., 2008) and infertility (Deepinder et al., 2007; Hamamah et al., 1993, 1998).  Studies on 
cerebrospinal fluid have associated metabolite changes with brain tumors and neurodegenerative disor-
ders, such as multiple sclerosis and Alzheimer’s disease (Han et al., 2011). Salivary metabolomics has 
been used to investigate oral cancer and pre-malignant changes, such as leukoplakia (Wei et al., 2011). 
Thus, this minimally invasive approach has enormous potential in providing valuable scientific and clini-
cal information for medical professionals and researchers. 
2.3.2     NMR Spectroscopy of Tissues and in vivo Imaging Techniques  
High-resolution magic-angle spinning (HR-MAS) NMR spectroscopy can be used to perform non-
destructive metabolite profiling of tissue or other solid samples (Keifer, 2007). That means that after HR-
MAS NMR spectroscopy, further testing of tissue samples can be performed such as histopathological 
evaluation, the current gold standard in disease diagnosis, or genome and protein sequencing. As a result, 
HR-MAS NMR has been used to investigate a number of disease states (Brown et al., 2012; Dittrich et 
al., 2012; Kurhanewicz et al., 2002; Martínez-Bisbal et al., 2004; Maxeiner et al., 2010; Millis et al., 
1997; Sitter et al., 2002). 
Metabolomic analysis can also be performed directly in vivo, largely owing to advances in mag-
netic resonance spectroscopic imaging and positron emission tomography (PET). A standard clinical 
magnetic resonance imaging (MRI) scan uses similar physical concepts to NMR, but takes many scans 
across a section of living tissue. This data is processed to produce an anatomically correct image based 
on physical properties of the tissue. A magnetic resonance spectroscopy imaging sequence is able to pro-
duce NMR-like spectra for a targeted volume segment in the body, allowing for visualization of metabo-
lite content in that anatomical location. Metabolic alterations measured in vivo have been shown to corre-
late with histopathology (Delongchamps et al., 2011; Kwock et al., 2006). Furthermore, in vivo metabo-
lomics is being used to monitor the response to various therapies, such as radiotherapy and chemotherapy 
(Coy et al., 2011; Lodi & Ronen, 2011).  
Different MRI techniques allow the investigation of different phenomena. Dynamic contrast-
enhanced MRI uses the uptake and elimination of contrast agents, such as gadolinium, to distinguish be-
tween different tissues. The use of dynamic contrast-enhanced MRI in oncology is based on the premise 
that cancer cells have a higher metabolism, and thus a higher uptake and elimination of gadolinium con-
trast (Vargas et al., 2012). Diffusion weighted imaging, initially used to investigate connectivity between 
different brain regions (Behrens et al., 2003), uses slower water diffusion in cancerous tissues compared 
 with surrounding healthy cells due to a higher nuclear content and cellular density coupled with extracel-
lular changes (Lim & Tan, 2012). Recently, these MRI techniques have been combined into multipara-
metric MRI, which has been shown to increase accuracy in cancer detection (Hoeks et al., 2011). The 
value of these in vivo applications and their role in oncology is commonly described and reviewed in ra-
diology literature (Hoeks et al., 2011; Hoh et al., 1997; Koh & Collins, 2007; Padhani, 2002). 
Further understanding of altered metabolism in cancer and identification of abnormal pathways fa-
cilitates imaging using PET in combination with computed tomography (CT) via PET/CT (Basu et al., 
2011; Jones & Price, 2012). After identifying metabolites, that are either preferentially used or upregulat-
ed within particular pathways, nuclear isotopes can be chemically attached either to these metabolites or 
to metabolite analogues. The emission of positrons from these isotopes can then be measured as gamma 
rays and superimposed on a CT scan during PET/CT scanning. For example, most cancer cells display 
heightened glycolysis. Thus, fluoro-deoxy-glucose, containing a radiolabeled positron emitter such as 
18F, can be administered and taken up by cancer cells, which are highlighted (Costello & Franklin, 2005). 
In addition, PET is able to distinguish specific cancers, e.g. 11C-choline PET is used to detect prostate 
cancer (Evangelista et al., 2012; Reske et al., 2006).The application of PET in other clinical scenarios is 
diverse, but widespread use is limited by logistical and financial constraints (Fletcher et al., 2008; Kelloff 
et al., 2005; Rohren et al., 2004).  
Recently, a novel method has been proposed to perform in vivo metabolomics during surgery by 
using real-time MS analysis of the smoke produced from electric cautery to biochemically recognize ma-
lignant/diseased tissue in which macroscopic changes are not present (Balog et al., 2010; Kinross et al., 
2011). Although major development is required before clinical use, the initial concept is intriguing in its 
potential to improve surgical accuracy and treatment outcomes following cancer surgery. 
2.4    Integration with other -Omics Sciences 
Metabolites are part of the complex and interconnected cellular hierarchy involving DNA, RNA, proteins 
and metabolites, as outlined in Figure 1. Consequently, providing an understanding of the mutual rela-
tionships between genomic, transcriptomic, proteomic and metabolomic data is a major aim of systems 
biology.  
Integration of multi-omics data sets is already providing insight into biological processes. This in-
tegration is enabled by the availability of new statistical methods to correlate information contained in 
multiple large datasets (Rantalainen et al., 2006). Furthermore, ever increasing genome-wide association 
studies (GWAS) are identifying multiple risk loci associated with various disease states. However, the 
penetrance of these loci, and therefore their relevance, remains unclear. By integrating metabolomics and 
other –omics sciences with GWAS, it is anticipated that identification of loci with a high pene-
trance/phenotypic manifestations will be unveiled (Suhre et al., 2011; Weckwerth, 2011). Integration of  
–omics data sets has major potential in oncology (Casado-Vela et al., 2011) and some studies have used a 
targeted approach in relating datasets obtained by different analytical methods (Rantalainen et al., 2006). 
A recently published study related metabolomic changes to genomic disturbances in PCa tissue to 
demonstrate alterations in m-aconitase and acetyl citrate lyase. Phospholipase A2 group VII and choline 
kinase α were responsible for altered citrate and choline levels, respectively (Bertilsson et al., 2012). 
Other integrative works investigated colorectal cancer (Ma et al., 2012a), heart failure (Lin et al., 2011) 
and other diseases (Adamski, 2012; Chen et al., 2012). These studies show impressive proof of concept 
 of this new approach. As a result, multivariate statistical analysis and integration of large and multi-
omics data sets are a valuable strategy for further investigation. 
 
 
Figure 1: Major targets for exploratory analysis in systems biology. The flow of in-
formation and biochemical processes between various levels in cellular organisation il-
lustrates the progression from genotype to phenotype (solid arrows). The individual 
levels of cellular organisation are also regulated by complex intrinsic feedback mecha-
nisms (dashed arrows). Adapted from (Roberts et al., 2011) 
Another key frontier in systems biology is the creation of genome-wide in silico models of cellular 
metabolism that are able to incorporate and integrate multi-omic data (Bordbar & Palsson, 2012). Such 
reconstructed metabolic networks have already suggested improvements for targeted treatment strategies 
of cholesterol homeostasis in human cellular models (Mo et al., 2007).  
The first genome-scale model of human metabolism published in 2007 was a promising milestone 
(Duarte et al., 2007). The next step in metabolic modeling in oncology will be to construct cancer-
specific metabolic models that will incorporate –omics data. This daunting task requires improved cura-
tion and annotation of genome databases, as well as integration of high quality –omics datasets from 
studies of specific cancer types, or of other disease states to create disease-specific reconstructions. Pub-
lic accessibility and maintenance of data from publicly funded research is critical to these efforts (Field et 
al., 2009), as is data management (Sansone et al., 2012) and interpretation (Leader et al., 2011). 
2.5    Analytical Techniques 
Of the many analytical techniques that are used in metabolomics to investigate physiological and 
pathological states, NMR spectroscopy and gas chromatography (GC) or liquid chromatography (LC) 
combined with MS are the two most commonly used methods. Both have low running costs, are diverse 
in sample type and allow for accurate metabolite identification. Other techniques in use are ultra-
 performance LC-MS, inductively coupled plasma MS, Fourier-transform MS, Fourier-transform infrared 
spectrometry and thin layer chromatography (Zhang et al., 2012). We will briefly describe the processes 
involved in MS-based metabolomics, with more extensive reviews available elsewhere (Dunn et al., 2005; 
Dunn & Ellis, 2005; Lu et al., 2008; Mishur & Rea, 2012; Pasikanti et al., 2008; Theodoridis et al., 
2008). Subsequently, we will focus on NMR-based metabolomics, describing the basic principles and 
statistical approaches that are currently in use. 
2.5.1    GC-/LC-MS 
Mass spectrometry detects ionized compounds in biological samples according to their mass/charge (m/z) 
ratio following chromatographic (e.g. GC or LC) separation, and metabolites can be identified in the re-
sulting mass spectrum with reference to internal standards (Wilson et al., 2005). LC- and GC-MS are 
well used techniques in metabolite analysis and have similar sensitivity, with the major difference being 
that GC requires more sample preparation (derivatization) and higher analysis temperatures, thus LC may 
be preferred for this reason (Issaq et al., 2009; Mishur & Rea, 2012). We will briefly outline the basic 
processes in MS-based metabolomics, which are sample preparation, separation (via liquid-/gas-
chromatography), ionization, mass analysis and detection, and finally, data processing.  
Sample preparation for MS is dependent on the type of sample. Simple biofluid preparation often 
involves removing macromolecules through protein precipitation and centrifugation or filtration. Similar-
ly, sampling of the exometabolome (metabolites secreted by cells or organisms into the growth medium) 
is straightforward. In contrast, to obtain intracellular metabolites, tissues or cells need to be extracted in 
an appropriate solvent system (Mishur & Rea, 2012). As different solvent systems are biased towards 
particular classes of metabolites (e.g. polar extraction systems yielding predominantly polar metabolites), 
the exact choice of solvent depends upon the metabolites of interest. To achieve consistency between 
samples, internal standards are typically added during/after extraction (Mishur & Rea, 2012).  
In GC-MS, derivatization is a further necessary preparation step, which is applied to non-volatile 
metabolite classes, such as amino and organic acids, sugars, amines and lipids, to render them volatile 
and thermally stable for GC (Dunn et al., 2005; Dunn & Ellis, 2005; Mishur & Rea, 2012). Derivatiza-
tion can introduce bias towards individual metabolites if the derivatizing agents are not provided in ex-
cess, as the derivatizing reactions have different efficiencies with different metabolites (Mishur & Rea 
2012). In addition, metabolites with multiple exchangeable protons will create multiple derivatization 
products that will show up as separate peaks, thus complicating the final mass spectrum. For GC-MS, 
electron impact ionization is almost exclusively used (Dunn et al., 2005). 
LC-MS is rapidly replacing GC-MS as method of choice in metabolomics, as both methods are 
similarly sensitive, but sample preparation for LC-MS is simpler, because derivatization is not required 
(Griffin & Shockcor, 2004). LC typically runs as reverse-phase high-performance LC (HPLC), or recent-
ly even as ultra-performance LC (UPLC), and electrospray ionization is typically used in LC-MS systems 
(Mishur & Rea, 2012). Electrospray ionization MS can run in positive or negative ionization mode, and 
because individual metabolites are generally only detected in one of those two modes, both ionization 
modes need to be run to improve coverage of the metabolome (Dunn & Ellis, 2005).  
In the resulting mass spectrum, metabolites are quantified by external calibration or by comparison 
with internal standards (Dunn & Ellis, 2005). GC-MS experiments may also require the use of deconvo-
lution software to adequately analyse overlapping chromatographic peaks (Dunn & Ellis, 2005). To allow 
comparable results between experiments, data may also undergo further pre-treatment steps, including 
 spectral alignment and automated picking of metabolite peaks (Dettmer et al., 2007). The subsequent 
multivariate analysis of processed MS data is similar to data obtained by NMR-spectroscopy. 
2.5.2    NMR Spectroscopy 
NMR spectroscopy is a quantitative technique used to accurately determine metabolite concentrations in 
samples. Chemical compounds in biological samples are identified by their characteristic peak patterns 
and signal positions in the NMR spectrum with the aid of online databases (Wishart et al., 2009) 
(http://www.metabolomicssociety.org/database). More comprehensive accounts of NMR theory and ap-
plication in metabolomics are available in dedicated texts (Ross et al., 2007). A comparison of the 
strengths and limitations of NMR and MS is provided in Table 1. 
Technique Advantages Limitations 
NMR - high reproducibility 
- high resolution 
- non-destructive 
- quantitative 
- low running costs  
- minimal sample preparation/no derivatization 
- unbiased metabolite profile 
- analysis of tissue (HR-MAS) 
- translation to in vivo (MRI) 
- rapid analysis 
- ability for automation 
- structural identification (2D, 3D) 
- low sensitivity 
- peak overlap 
- libraries of limited use due to 
complex matrix 
- long acquisition times for 
heteronuclear techniques, e.g. 
13C 
- high initial capital cost - re-
duced  
availability  
GC-MS - high sensitivity 
- large linear range 
- robust 
- identification of wide range of metabolites  
(wider range with LC-MS) 
- analysis of complex biofluids 
- non-targeted 
- established databases 
- widely available and comparably low capital 
cost  
- preferred for targeted analysis 
- slow 
- sample unable to be re-used 
- requires chemical derivatiza-
tion 
- potentially multiple derivati-
zation products for metabo-
lites 
- many analytes thermally un-
stable 
- metabolite weight limitation 
(<1400 Da) 
LC-MS - high sensitivity 
- high reproducibility 
- large linear range 
- no chemical derivatization needed 
- slow 
- limited commercial libraries 
- sample unable to be re-used 
- generation of adducts 
- higher capital cost (HPLC-
MS) 
Table 1: Comparison of the advantages and disadvantages of NMR, GC-MS, and LC-MS 
(Issaq et al., 2009; Shepherd et al., 2011; Shulaev, 2006; Zhang et al., 2012). 
 2.6    Processing of NMR Data 
Processing of NMR data comprises four steps: Fourier transformation, phase correction, baseline correc-
tion and calibration. Fourier transformation transforms the raw real-time data into the frequency domain, 
and phase correction corrects the phase of the resulting NMR spectrum. Baseline correction ensures a 
constant zero baseline across an NMR spectrum, and calibration is needed to ensure a consistent chemi-
cal shift scale/axis across all spectra. Inadequate processing introduces artifacts that confound statistical 
analysis and jeopardize data integrity (see Figure 2).  Minimum standards for reporting and processing 
have been outlined (Goodacre et al., 2007), and continue to be a good guide for authors publishing 
metabolomics research.
Usually, NMR spectra require a phase correction following Fourier transformation in order to 
achieve pure absorptive line shapes for all peaks in a NMR spectrum. Where possible, phasing should be 
performed automatically or by the same operator across all samples to ensure consistency. Incorrect 
phasing can distort peak integrals and thus, the subsequent multivariate statistical analysis (MVSA; see 
Figure 2A/2B).  
Baseline correction is the third critical processing step in producing consistent, comparable and re-
liable data in NMR spectroscopy. At a minimum, the y-offset of the entire spectrum is corrected to be 
zero. However, baseline corrections are often more complex, using spline, polynomial or other mathe-
matical functions to accomplish a zero baseline over the whole spectrum. As signal intensities are calcu-
lated with reference to zero, inadequate baseline correction will distort spectral peak intensities (Figure 
2B/2C), and compromise the subsequent MVSA.     
 
Figure 2: Sequential steps of processing NMR spectra. Shown is a spectrum of human ejacu-
late in the region of citrate (2.45 – 2.65 ppm) as example. Correct baseline position is illustrated 
with dotted lines. a - Spectrum after Fourier transformation. The phases of the NMR signals are 
partly dispersive and in need of phase correction. b - Spectrum after phase correction. Globally 
reduced metabolite peak intensities and negative values for the baseline occur across the entire 
spectrum. c - Spectrum after baseline correction, but requiring calibration to a chemical shift 
standard. Chemical shift values are incorrect across the entire spectrum, resulting in incorrect 
metabolite identification. d - Correctly processed spectrum suitable for data reduction. 
 Importantly, the chemical shift axis of each NMR spectrum must be adequately calibrated using a 
chemical shift standard, such as (deuterated) 4,4-dimethyl-4-silapentane-1-sulfonic acid-d6 (DSS). In 
samples containing a high protein content (such as plasma), DSS cannot be used as internal standard. 
Thus, other endogenous metabolites that are present across all samples, such as lactate, glucose or for-
mate, are used as internal reference. The alternative is to use DSS as an external standard by either insert-
ing a capillary with DSS in deuterium oxide (D2O) into the NMR tube, or inserting the sample in a capil-
lary into a tube containing DSS in D2O. The use of 4,4-dimethyl-4-silapentane-1-ammonium trifluoro-
acetate (DSA) has also been suggested as chemical shift standard that is not affected by protein binding 
(Alum et al., 2008). Chemical shift calibration ensures consistent global alignment of spectra in a metab-
olomics data set which is critical for statistical analysis. In addition, correct spectral alignment is required 
for reliable metabolite identification. However, even in correctly calibrated spectra, individual peaks can 
still exhibit differences in chemical shift between individual spectra due to differences in sample pH and 
ionic strength. These can be corrected post-processing by various automatic peak alignment procedures 
(Anderson et al., 2011; Giskeødegård et al., 2010; MacKinnon et al., 2012; Savorani et al., 2010; Staab 
et al., 2010; Wright et al., 2012). 
2.7    Statistical Pre-processing 
2.7.1     Data Reduction  
After processing of raw NMR data, further processing steps are needed to prepare data for MVSA, which 
are usually termed “statistical pre-processing”. Reducing the full resolution data into small segments of 
equal width, called bins, or “buckets” (Figure 3), is the most widespread method of data reduction in 
chemometrics (Wishart, 2008). Compared with analysis at full resolution, this method considerably re-
duces the size of the data matrix in MVSA, and is particularly helpful when peak positions or widths vary 
slightly due to changes in pH, ionic strength or other factors. However, due to decreasing data resolution, 
bucketing can complicate metabolite identification following data analysis. Other pre-processing meth-
ods that can be used, particularly in targeted metabolomics, include deconvolution, peak-picking, and 
weighting factors (Goodacre et al., 2007). 
 
 
Figure 3: Illustration of data reduction by “bucketing”. a - NMR spectrum of human ejaculate with 
suitable pre-processing (segment shown). b – Same spectrum segmented/data reduced into buckets of 
0.04 ppm width across the region 8 – 0 ppm. The region around the water signal from 5.08 – 4.52 ppm 
was excluded due to artifacts from imperfect water suppression. Note that the area in each individual 
bucket is integrated across the spectral width of 0.04 ppm and then normalized, yielding intensities 
similar to a histogram.  
 2.7.2     Normalization  
After data reduction, data need to be normalized to produce data that are comparable between samples 
(Craig et al., 2006). Normalization is a row operation in the data matrix, and different normalization 
methods are used to obtain the best representation of the data. In total integral normalization, or normal-
izing to total intensity, the spectral intensity in each bucket is divided by the total intensity of each spec-
trum. This procedure normalizes differences between spectra due to sample concentration/dilution, e.g. 
due to different water content between samples. However, total integral normalization is vulnerable to 
distortions when one or a few intense signals change considerably between spectra. 
Another method involves normalization to an internal reference compound. For metabolomics 
analysis of urine, normalization to creatinine has been widely used (Akira et al., 2008; Jentzmik et al., 
2010). For physiological reasons, urine creatinine is believed to be a suitable indicator of urine concen-
tration as creatinine excretion is constant. However, creatinine normalization has limitations because it 
will be confounded by any background pathophysiology that alters serum creatinine levels or creatinine 
excretion, such as in kidney disease. In these cases, creatinine normalization is not suitable. Furthermore, 
variations in chemical properties within the sample can distort creatinine alignment, so that other metabo-
lites, especially creatine, will overlap with the creatinine signal and thus impede the proper measurement 
of creatinine concentration (Ross et al., 2007).  
Probabilistic quotient normalization (PQN) is a method that reduces variation caused by large 
changes in the intensity of one or a few signals across samples, as shown in Figure 4. Thus, PQN can 
overcome the main weakness of total integral normalization. In PQN, which is usually performed after 
total integral normalization, each variable (bucket) in a spectrum is first divided by the intensity of the 
same variable in a reference spectrum. Afterwards the full spectrum is divided by the median of these 
quotients. This procedure is repeated for all spectra in a data set, using the same reference spectrum 
(Dieterle et al., 2006).    
Recently, Kohl et al. compared many normalization methods, with some derived from genomic 
data analysis, and recommended more advanced methods, such as quantile normalization for datasets of n 
! 50, as well as Cubic Spline Normalization and Variance Stabilisation Normalization (Kohl et al., 
2012).  
 
Figure 4: Schematic depiction of spectra containing four NMR signals A-D, following two different 
normalization methods. a – raw spectra with marked intensity variation present in the first peak A and 
identical intensities of remaining peaks between all spectra. b - Integral normalization (normalization 
to total intensity) reduces variation, and therefore influence of the dominant signal A, but also alters 
relative intensities of the smaller, previously identical signals.  c - Probabilistic quotient normalization 
(PQN) partially reduces variation and influence of the larger signal A, while maintaining the original 
relationships between smaller peaks to allow optimal comparison during MVSA.  
 2.7.3     Scaling Effects  
Following normalization, metabolomic data must be appropriately scaled, or transformed in a column 
operation in a way that changes how much signals of large and small intensity, respectively, influence the 
data analysis (Craig et al., 2006; Goodacre et al., 2007). The objective is to reduce noise and maximize 
information content in the data. Inappropriate scaling may lead to results that highlight parts of the data 
unrelated to a biological factor, thus compromising the analysis and biological interpretation of the data. 
In metabolomics statistical analysis, three scaling methods are largely used.  
Centre scaling, or mean centering, subtracts the mean value of each variable/bucket from the orig-
inal data of that bucket (Craig et al., 2006). This method is the least manipulative, and is also best at min-
imizing background noise, but large relative variations in small signals may not be detected. Mean cen-
tering is usually performed mandatorily. Thus, this method is also sometimes referred to as “no scaling”, 
as no further scaling is performed after mean centering.  
Univariate, or unit variance, scaling divides the raw data obtained after mean centering by the 
standard deviation of each variable. Univariate scaling gives each variable equal weighting, such that 
variables with small absolute but large relative variation are highlighted, but this also means that back-
ground noise and other unrelated data variation may be overemphasized and thus confound the analysis 
(Craig et al., 2006).  
Pareto scaling is performed by dividing each variable by the square root of its standard deviation 
(Erikson et al., 1999). This is the recommended scaling method for NMR-based metabolomic data, as it 
is able to increase the weighting on metabolites with smaller amplitudes, but does not overemphasize the 
influence of background noise.  
2.8    Statistical Analysis 
Statistical analysis of metabolomic data depends on the biological question studied and the design of the 
particular project, thus, the choice of data analysis methods varies between different projects. In addition, 
the methods for data analysis are continually evolving. Nevertheless, there is a core set of methods of 
univariate and multivariate statistical analysis that is in use for metabolomics, and minimum reporting 
standards for data analysis have been established (Goodacre et al., 2007; Liberati et al., 2009; Schulz et 
al., 2010).  
2.8.1     Univariate Statistical Analysis  
The role of univariate analysis in metabolomics is largely of a targeted nature. An example would be 
where metabolites of interest have been identified by MVSA, and detailed analysis of statistical signifi-
cance of the individual metabolites is desired. Basic univariate methods can be used to analyze whether 
or not individual metabolites are significantly different between two classes. However, as with any statis-
tical analysis, the distribution of the data determines the type of analysis used. If the data are normally 
distributed, t-tests, z-tests, and analysis of variance (ANOVA) may be used. In cases where the distribu-
tion is not normal, non-parametric methods such as the Kruskal-Wallis test are used (Goodacre et al., 
2007). However, given the high number of variables within a metabolomics dataset, use of multiple hy-
pothesis testing corrections, such as Bonferroni correction or false discovery rate/Benjamini-Hochberg 
are absolutely imperative (Noble, 2009). This means that, to be significant, p-values need to be much 
 smaller (e.g. p ≤ 5 × 10-5) after correcting for multiple hypothesis testing compared to standard univariate 
statistical analysis (Broadhurst & Kell, 2006).  
2.8.2     Multivariate Statistical Analysis (MVSA)  
Modern day metabolomics is largely based on data sets incorporating many variables, between several 
hundred in the case of bucketed data and up to 65,536 if 1D-NMR spectra are used at full resolution.  
Thus, MVSA methods which simultaneously analyze all these variables are preferred (Broadhurst & 
Kell, 2006). MVSA determines whether there are inherent patterns or groupings within the data that cor-
respond to biological states and also which variables are important in discriminating between the differ-
ent groupings. Thus, this approach is well suited to analyzing metabolomics datasets, where the aim is to 
correlate multiple metabolite changes with alterations in biology.  
 
Approach Method Advantages Disadvantages 
Unsupervised Principal 
components 
analysis 
(PCA) 
• Simplifies data 
• Describes variation in original data without bias 
• Groups samples with similar metabolite profiles 
• Variation might 
be unrelated to bi-
ological question  
• Influenced by any 
confounders  
Supervised Partial least 
squares (PLS) 
• Simplifies data  
• Groups samples with similar metabolite profiles  
• Extracts variation that is correlated with  external 
data/identifiers  
• more directed to the biological question 
• Possibility of in-
troducing bias  
• Require rigorous 
validation 
Orthogonal 
projections to 
latent struc-
tures (OPLS) 
• As PLS 
• Removes orthogonal (unrelated) variation 
• Improved knowledge extraction 
2-way OPLS 
(O2PLS) 
• As OPLS 
• Two-way data correlation between X and Y 
• Potential for unsupervised analysis (when analyz-
ing two large datasets without external Y table) 
Kernel OPLS • As OPLS 
• Improved model prediction 
OnPLS • As O2PLS 
• Simultaneous data correlation from multiple (n) 
matrices 
• Possibility of in-
troducing bias  
• Require rigorous 
validation 
• Not widely avail-
able (commer-
cial/open source) 
Bi-modal 
OnPLS 
• As OnPLS 
• Data correlation between  variables (columns) and 
samples (rows) 
OnPLS path 
modelling 
• As OnPLS 
• Linkage of matrices along statistically related 
paths  
Table 2: Summary of multivariate statistical analysis methods used in metabolomics for information 
recovery. The advantages and disadvantages of unsupervised and supervised methods are outlined. 
 There are two general classes of MVSA methods: unsupervised methods, which analyze patterns 
within a data matrix X, and supervised methods in which the patterns in X are correlated with other exter-
nal data (e.g. clinical data) contained in a Y matrix or Y table. The advantages and disadvantages of the 
most common MVSA methods are summarized in Table 2, and will be discussed in the following sec-
tions. Some examples of software programs, both commercial and free/open-source, that are available to 
perform MVSA are given in Table 3. 
 
Software Package Use in 
NMR/MS 
Reference/Source 
Commercial 
SIMCA Both http://www.umetrics.com 
MATLAB Both http://www.mathworks.com 
MarkerLynx/MassLynx MS http://www.waters.com 
STATISTICA Data Miner Both http://www.statsoft.com 
AMIX Both http://www.bruker.com 
Agilent Mass Profiler Professional MS http://metabolomics.chem.agilent.com 
Progenesis CoMet MS http://www.nonlinear.com 
Free/Open Source 
R Both http://www.r-project.org 
Metaboanalyst Both http://www.metaboanalyst.ca (Xia et al., 2012) 
MAVEN MS http://maven.princeton.edu (Melamud et al., 2010) 
MZmine MS http:// mzmine.sourceforge.net (Pluskal et al., 2010) 
MeltDB MS https://meltdb.cebitec.uni-bielefeld.de/ (Neuweger et al., 2008) 
MetabolomeExpress MS https://www.metabolome-express.org (Carroll et al., 2010) 
Table 3: Examples of software packages used to perform multivariate statistical 
analysis in metabolomics. 
2.8.3     Unsupervised Methods in Multivariate Statistical Analysis  
Often, unsupervised analysis methods are initially used in MVSA as they are excellent data exploration 
tools that can be either used to simplify the data (dimensionality reduction – principal- or independent-
components analysis) or to group samples with similar metabolite patterns (clustering – hierarchal, parti-
tional). Although many different methods exist, principal components analysis (PCA) is the most com-
monly used method of unsupervised analysis in metabolomics. 
PCA simplifies the original multivariate data which form a swarm of data points in a high-
dimensional statistical space, by projecting them down into a new space with comparatively few dimen-
sions called principal components (PCs). These PCs are latent variables that describe the variation in the 
original data. The first PC indicates the direction in which most variation occurs in the data. Subsequent 
PCs are all orthogonal to each other and sorted in order of descending amount of variation. This ar-
rangement describes the majority of variation in the data within the first few PCs. PCA is visualized by 
two types of plots, the scores and loadings plots (Figure 5).  
The scores plot illustrates the relationship and similarity of samples to each other, and allows for 
inspection of groupings and outliers. Outliers can be visually identified on the scores plot, or statistically 
defined as being outside the Hotelling’s 95% confidence range across all components. Further statistical 
validation can be obtained using the residual variance of the model, known as distance to model plot 
 (Erikson et al., 1999; Trygg et al., 2007).  The variables (buckets, ultimately metabolites) attributable to 
each component in the model are illustrated in the loadings plot (see Figure 5; Denkert et al., 2006; Pan 
et al., 2007). 
 
 
Figure 5: Visualization of a typical multivariate analysis (e.g. PCA, PLS etc.). Sheep urine 
samples before and after road transport of 12 and 48 hours are shown as an example (Li et al., 
2010). a – Scores plot – shows any relationships between samples, such as the presence of 
separate groups or outliers. This scores plot shows similarity of the pre-transport groups for 
both transport durations (open inverted triangle = 12 h, black squares = 48 h), and differences 
between both post-transport groups (48 hours = black diamonds, 12 hours = open triangles). b 
– Loadings plot – displays the relationship of influential variables that are responsible for the 
position of outliers or groups seen in the scores plot. Note that the positions/directions of 
groupings/outliers in the scores plot and responsible variables in the loadings plot correspond 
to each other (Trygg et al., 2007). 
The inherent advantage of unsupervised methods is that they are unbiased, i.e. they detect any sta-
tistical variation in the data, whether or not it is related to the underlying biological effect (e.g. differ-
ences between cancer and non-cancer samples). This property is also their most noticeable limitation, 
because when confounding effects are larger than the biological effect, unsupervised analyses will pre-
dominantly show the effects of these confounding factors. Distorting variation may also come from un-
correlated background variation, or from noise. For this reason, robust experimental design that limits 
confounding factors and appropriate pre-processing prior to data analysis are vitally important to ensure 
meaningful results. 
2.8.4     Supervised Methods in Multivariate Statistical Analysis (MVSA) 
MVSA can be improved by including external data, such as clinical data, in a Y table or Y matrix. This 
data inclusion then makes it possible to use a different class of MVSA methods, which are called super-
vised analysis methods. The biggest advantage of supervised methods is that they can identify the varia-
tion (and associated variables) in the biological data that is correlated (or co-varies) with the external 
data, i.e. they improve information recovery and thus interpretation of the biological data. The main su-
pervised methods used in metabolomics-based biomedical research are partial least squares (PLS) and 
 orthogonal projections to latent structures (OPLS) (Gu et al., 2011; Pan et al., 2007; Trygg & Lundstedt, 
2007).  
PLS is a method that seeks to identify correlation between the dataset matrix (X) and one or multi-
ple variables (contained in Y). Y data may be categorical (class identities, e.g. healthy vs. disease) or con-
tinuous (blood pressure, height etc.). If the external variable(s) are qualitative, then the method will dis-
criminate between the corresponding classes and is known as PLS discriminant analysis (PLS-DA) 
(Trygg et al., 2007).  Figure 6 illustrates this distinction. Supervised analyses in metabolomics can be 
affected by systematic variation that is unrelated to the class, as this affects any correlation found by the 
analysis method. 
 
                  
Figure 6: Data included in a PLS analysis. The X table/matrix comprises the metabolomic data 
following pre-processing. Depending on the objective of the analysis, the Y table/matrix can 
include continuous (PLS) or categorical (PLS-DA) data to which the X data are correlated. 
OPLS is an improvement on PLS that separates variation in the data into two parts: one that is cor-
related with the biological factor(s) and one that is unrelated/orthogonal, i.e. OPLS separates X into var-
iation that is predictive of Y and variation that is orthogonal to Y (Brindle et al., 2002; Trygg et al., 2002, 
2003, 2007; Wagner et al., 2005). A further development of OPLS is 2-way OPLS (O2PLS). While 
OPLS only correlates data in X with Y, O2PLS is able to correlate X and Y with each other in both direc-
tions (Trygg & Wold, 2003). In addition, individual variables from an O2PLS analysis can be visualized 
as a bivariate 1D loadings plot facilitating identification of potential metabolites (Cloarec et al., 2005). 
Both, OPLS and O2PLS have recently been preferred to PLS, as separation and correlation of predictive 
variation to the Y table has been shown to optimize discriminant analysis, improving overall knowledge 
extraction (Bylesjö et al., 2006; Pinto et al., 2012; Wiklund et al., 2008). This is because both predictive 
and orthogonal variation can be examined, which may provide more detailed insight into the factors in-
 fluencing the biological system (Kirwan et al., 2012). Furthermore, O2PLS can be used to correlate two 
different data sets with each other, e.g. metabolomic and proteomic datasets in an animal model of pros-
tate cancer (Rantalainen et al., 2006). If applied in this way, O2PLS is essentially an unsupervised analy-
sis that is able to correlate variables of different datasets, providing further insight into related structures 
and pathways in altered metabolic states (Bylesjö et al., 2007).  
Different extensions of OPLS or O2PLS have been published, including kernel-OPLS, which im-
proves model prediction (Rantalainen et al., 2007).  OnPLS is an extension of O2PLS which determines 
correlation not only between two, but multiple (n) matrices, allowing for integration of any number of 
datasets for a given study (Löfstedt & Trygg, 2011). Bi-modal OnPLS is an extension to OnPLS that is 
not only able to analyze orthogonal variation in variables (columns), but also in samples (rows) (Löfstedt 
et al., 2012a). This bi-modal approach should provide more informed data analysis, of both, the variables 
associated to the biological question, and of confounding factors associated to particular samples. Finally, 
OnPLS path modeling is a method of linking multiple matrices along a set of paths that flow between 
data blocks. These paths are assumed to be due to a specific causative mechanism, e.g. changes over 
time, and are able to extract the minimum number of predictive components that have maximum covari-
ance and correlation (Löfstedt, et al., 2012b). Use of these recent extensions of O2PLS is not yet wide-
spread, but highly promising in improving metabolomic data analysis. 
 
 
Figure 7: Validation by permutation analysis. a – Example of a valid model (original R2 and 
Q2 plotted on right side of panel), with permutations resulting in models that are less predic-
tive (plotted on left side of panel). The x-axis indicates the distance of the permuted model to 
the original model, and the y-axis indicates R2 and Q2. b – Example of an invalid model, with 
permutations resulting in models with similar or improved predictability. 
One inherent problem of any supervised MVSA method is that, because they attempt to correlate 
the experimental data (X) with external data (Y), they are prone to introducing bias in the analysis. This 
can happen due to overemphasis of spurious correlations in the data that are only coincidental and not 
caused by biology. As a result, MVSA models have to be rigorously validated when compared to unsu-
pervised analysis methods. The value of a validated supervised model may be higher than that of a model 
originating from unsupervised methods because supervised methods are more directed toward the biolog-
ical question. There are several methods of validation. The gold standard is the use of an independent set 
of data to test the predictive power of the original (training) set of data, combined with external cross-
 validation of the training data set. An established alternative is permutation analysis in which the data in 
the Y table are repeatedly permuted at random and the model recalculated with the permuted Y data 
(Westerhuis et al., 2008). If the model is stable and correlations to Y are only of biological origin, ran-
domization and permutation of Y data will reduce the fit and predictability of the model (see Figure 7A). 
Weak models in which correlations to Y are due to chance, rather than biology, will produce permuted 
models that may provide similar or superior prediction than the original model and are thus invalid (see 
Figure 7B).  
Measures of validity in this context are the R2 value, which measures goodness of fit, and Q2, 
which measures model prediction ability. However – similar to cross-validation – permutation analysis 
becomes less trustworthy the lower the ratio between number of samples (n) and variables (k) is. The 
turning point may be near a ratio of n/k of < 0.02 – 0.04, although this is not applicable for all data sets, 
and each study has to be evaluated on its own merits (Rubingh et al., 2006). In situations where valida-
tion via permutation analysis is not easily accessible, cross-validated ANOVA can be used which uses 
cross-validated predictive residuals using two degrees of freedom for each component, and is more relia-
ble than ANOVA which uses fitted residuals (Eriksson et al., 2008).  
3    Current Evidence: Metabolomics in Prostate Cancer 
3.1    Prostate Cancer Pathophysiology 
Prostate cancer (PCa) is the most common internal cancer in men worldwide and is more prevalent and 
lethal in Western countries (Siegel et al., 2012). Continually evolving methods for early PCa detection 
have improved outcomes due to earlier treatment and a better prognosis for patients. Current methods of 
detection (serum prostate-specific antigen (PSA) and/or digital rectal examination) leading to diagnosis 
(via trans-rectal ultrasound (TRUS) guided biopsy) require improvement due to limited diagnostic sensi-
tivity and specificity. Improved methods will help to avoid morbidity in men for whom a diagnosis of 
PCa remains elusive due to limitations and problems associated with TRUS-guided biopsy, as is the cur-
rent situation. Thus, PCa pathogenesis has been extensively studied to facilitate the discovery of new 
methods for determining the presence of PCa. 
The prostate gland sits in the pelvis below the bladder and in front of the rectum. It is a secretory 
gland that contributes to the seminal fluid component of ejaculate/semen to facilitate sperm motility and 
egg fertilization in utero. The secretory portion of the gland is called the peripheral zone (PZ), and con-
stitutes 70% of the gland volume. The epithelium within the PZ secretes prostatic fluid, which contains 
proteins, such as prostatic acid phosphatase and prostatic specific antigen (PSA), and metabolites, such as 
citrate and polyamines (e.g. spermine) (Costello & Franklin, 2009). Furthermore, prostatic cells have 
been shown to be present in EPS and ejaculate, which makes both biofluids suitable media for molecular 
analysis (Gardiner et al., 1996).  
Citrate production, after sequestration, by PZ epithelium results in a higher citrate concentration in 
EPS when compared with blood plasma (Costello & Franklin, 2009). This process is facilitated by zinc-
dependent truncation of the tricarboxylic acid cycle by inhibiting the enzyme m-aconitase, as shown in 
Figure 8.   
ZIP1 is the primary transporter for zinc ions in PZ epithelium, and is expressed by the ZIP1 gene, 
which has consequently been described as a tumor suppressor gene in PCa (Costello & Franklin, 2006). 
 The expression of ZIP1 and other zinc transporters recently has been described as being regulated by the 
micro-RNA cluster miR-183-96-182 (Mihelich et al., 2011). Zinc ions inhibit m-aconitase, which con-
verts citrate to isocitrate, the first step of the citric acid cycle. As a result, the preferential sequestration of 
zinc ions in the PZ epithelium causes citric acid cycle truncation, producing an increased glucose re-
quirement within the PZ epithelium. 
 
Figure 8: Pertinent physiology of the healthy PZ epithelium. Biochemical reactions are 
shown by solid/open arrows and regulatory interactions by dashed arrows. When healthy, 
ZIP1 mediated uptake of zinc inhibits isomerization of citrate to isocitrate by m-aconitase. 
The result is high intracellular concentrations of zinc ions and citrate, which are secreted to 
aid in fertilization. Adapted from (Costello & Franklin, 2009; Roberts et al., 2011).   
The resulting high citrate and Zn2+ concentrations in PZ epithelium are reflected in EPS. Citrate is 
important in seminal ion homeostasis, and is the predominant regulator of calcium ions, which are im-
portant in the motility, metabolism and fertilization functions of sperm (Owen & Katz, 2005). Levels of 
zinc ions are correlated with those of other cations, such as calcium and magnesium, but are considerably 
higher in concentration. In semen, these cations are largely redistributed in binding to negatively charged 
seminal vesicle proteins, such as seminogelins, which are vital in regulating sperm function (de 
Lamirande, 2007). In seminal fluid, zinc ions are bound mostly to metallothionein, with changes in levels 
of zinc being paralleled by those of this protein which is mostly derived from the prostate itself (Suzuki 
et al., 1994).  
3.1.2    The Malignant Prostate 
Malignant transformation of cells is the result of irreversible genetic alterations, most commonly due to 
mutations. Specific to PCa, malignant transformation impairs Zn2+ accumulation, removing zinc-
mediated inhibition of m-aconitase. The result is completion of the citric acid cycle and increased ATP 
production via oxidative phosphorylation. This is reflected by low zinc and citrate concentrations present 
in PZ epithelium and prostatic fluid, which have been investigated as potential biomarkers (Costello & 
 Franklin, 2009). Further alterations in gene expression impair normal mitochondrial functioning. Coupled 
with the relatively rapid division and increased basal metabolic rate in cancer cells, increased glycolysis 
and lactate fermentation in the presence of oxygen occurring in the malignant state increases glucose up-
take, as well as proteolysis and subsequent alanine production. Pyruvate is produced in excess of what 
can be processed by the tricarboxylic acid cycle, and is converted to lactate. This is known as the War-
burg effect, and is seen as a marker of advanced disease in prostate and other cancers (Bayley & Devilee, 
2012; Warburg, 1956). This process is outlined in Figure 9. Furthermore, increased membraneogenesis 
accompanying increased cellular proliferation adds to the changes in the metabolite profile with 
malignant transformation, and requires synthesis of choline and creatine, which have been shown to be 
elevated in malignant prostate tissues (Noworolski et al., 2008). 
 
Figure 9: Pathophysiology of the PZ epithelium after malignant transformation. Impaired zinc uptake 
reduces inhibition of m-aconitase, resulting in citrate isomerization and completion of the TCA cycle. 
Alanine is produced secondary to proteolysis and lactate as a consequence of the Warburg effect.  
Adapted from (Costello & Franklin, 2009; Israël & Schwartz, 2011; Roberts et al., 2011). 
3.2    Individual Biomarkers 
A single biomarker that is able to confirm the presence of an altered biological process or indicates pro-
gression of a disease is a valuable asset in prompting appropriate management for any medical condition 
to improve the outcome for a particular patient. For instance, extremely high serum levels of the human 
hormone !-chorionic gonadotropin (#-hCG, a marker normally used in pregnancy) in a male patient with 
a small testicular mass strongly indicate the presence of choriocarcinoma. While this is an example of an 
ideal biomarker, such biomarkers do not currently exist for most scenarios in oncology, particularly in 
PCa (Cole, 2009).  
3.2.1    Serum 
The most widely used biomarker for PCa is serum human kallikrein 3, also known as prostatic-specific 
antigen (PSA). PSA is a serine protease that is normally secreted in seminal fluid to catalyze proteolysis 
 of seminal proteins, such as seminogelin (Lilja, 1985). PSA is elevated in blood in the presence of PCa as 
well as with other prostatic conditions, such as bacterial prostatitis and benign prostatic hyperplasia 
(BPH). Despite not being specific for cancer, PSA is clinically valued and widely used (Clarke et al., 
2010).  
The normal range of serum PSA, based on population studies, is defined as <1.0 ng/ml. Serum 
PSA is not only frequently elevated in other disease states, but can also change in the absence of patholo-
gy due to other confounders, such as racial and environmental variables (Henderson et al., 1997; Marks 
et al., 2006; Vollmer, 2004). In biomarker research, often a cut-off point is derived from studies to de-
termine the optimal sensitivity (i.e. the ability of the test to accurately predict true negative patients) and 
specificity (i.e. the ability of the test to predict accurate true positive patients). A vast body of evidence 
has shown that a safe cut-off value for PSA does not exist (Schröder et al., 2000; Thompson et al., 2004). 
Safety in this context refers to a level that is low enough to detect the majority of men with cancer, but 
not so low as to cause extensive and unnecessary investigation of men without cancer. This finding of the 
absence of a safe cut-off value for PSA has been used as one of the major arguments against population 
screening for PCa using PSA (Catalona et al., 2012; Moyer, 2012).  
Serum PSA is a clinically valued test when used with discrimination, and various adaptations have 
been discovered and trialed with varying success, though none has been considered superior to total se-
rum PSA itself (Auprich et al., 2012; Roobol et al., 2009). Examples include free to total PSA levels, 
PSA velocity and doubling time (time course of an increase by a factor of two), PSA density (serum PSA 
in relation to the prostate volume determined by TRUS) and, most recently, the prostate health index 
which incorporates serum PSA, pro-PSA and percentage free PSA (Catalona et al., 2011; Hori et al., 
2012; Lughezzani et al., 2012).  
Other serum biomarkers in PCa diagnosis vary in type and size, from circulating tumor cells 
(Danila et al., 2011; Doyen et al., 2012), to microRNAs (Catto et al., 2011; Sevli et al., 2010), with small 
molecules and ions, such as sarcosine and zinc, having yielded inconsistent results as markers (Daragó et 
al., 2011; Li et al., 2005; Lucarelli et al., 2012; Struys et al., 2010). 
3.2.2    Urine 
Ideally, the perfect marker of PCa is sourced from a non-invasive sample/procedure and indicates both 
the presence and nature of the disease. Currently, the best urinary marker for PCa is PCA3, formerly 
known as differential display clone 3 (DD3) (Salagierski & Schalken, 2012). The PCA3 test relies on a 
patient having had a firm digital rectal examination or prostatic massage just before micturition with the 
flow of urine flushing dislodged prostatic cells in the prostatic urethra to beyond the external meatus with 
the void for collection, so there is some licence involved in calling this a urine test. PCA3 is a non-coding 
RNA which has been shown to be highly expressed in and specific for prostatic tissue (Bussemakers et 
al., 1999; de Kok et al., 2002; Landers et al., 2005). PCA3 in urine is expressed as a ratio to PSA RNA, 
and improves detection compared with serum PSA. Use of recently described PCA3 isoforms may fur-
ther improve results (Clarke et al. 2009; Haese et al., 2008; Hessels et al., 2003). PCA3 also contributes 
to and has been recommended for clinical decision making for men with previous negative biopsies but 
in whom clinical suspicion is high (Tombal et al., 2012), however its role in PCa detection has yet to be 
established clinically. Inclusion of the TMPRSS2: ERG fusion gene also has been reported to improve 
detection of PCa with reference to biopsy (Tomlins et al., 2011).  
 3.2.3    Seminal Fluid 
The main concern with tests using EPS is that both firm DRE / prostatic massage and TRUS biopsy tar-
get the posterior part of the prostate, and neglect anterior and anterolateral aspects of the gland in which 
up to 30% of PCa’s are sited (Quann et al., 2010; Samaratunga et al., 2007). In contrast, seminal fluid 
contains a prostatic component, which is the result of global smooth muscle contraction, and thus theoret-
ically reflects the pathological status of the whole gland. Furthermore, the ability to produce seminal flu-
id via ejaculation is an indicator of cardiovascular status, as erectile dysfunction is a known event in dete-
riorating cardiovascular status (Chew et al., 2011; Schouten et al., 2008). Thus, men who produce semi-
nal fluid are expected to have a more favorable mortality outcome following intervention with curative 
intent for PCa than men who are impotent since cardiovascular disease is the commonest cause of patient 
demise in this population. Prostatic tissue and prostatic fluid show similar levels of citrate and Zn2+, fur-
ther suggesting that prostatic fluid reflects intraprostatic pathophysiological status (Zaichick et al., 1996). 
3.2.4    Metabolite Changes in Seminal Fluid  
Historically, changes in citrate and Zn2+ in PCa have been the most pronounced and easily detectable in 
prostatic and seminal fluid (Cooper & Imfeld, 1959). Metabolite profiling and recent metabolomic analy-
sis of seminal fluid and EPS have discovered alterations in other metabolites, summarized in Table 3. 
Disturbed zinc homeostasis removes the inhibition of m-aconitase, resulting in citrate oxidation in the 
citric acid cycle. This causes luminal Zn2+ and citrate depletion. Zinc depletion only occurs in PCa, and 
has been shown to be a stable indicator of PCa status and progression (Zaichick et al., 1996).  
Although citrate levels are altered in other pathophysiological states, such as BPH and prostatitis 
(Cooper & Farid, 1964), reduced citrate concentrations in histologically benign prostatic tissue is consid-
ered to precede microscopic evidence of PCa (Dittrich et al., 2012). In poorly differentiated tumors, these 
normally abundant metabolites are present in very low concentrations (Kurhanewicz et al., 1993). This 
metabolite relationship in PCa has also been correlated with the Gleason histological scoring system and 
is more accurate than serum PSA (Kline et al., 2006). Such biochemical changes reflect early neoplastic 
processes that may not be histologically identifiable, a concept familiar in oncology as the “field effect” 
(Costello & Franklin, 2009). This further supports the role of metabolomics in identifying significant 
metabolic alterations in pre-malignant tissue.  
Other metabolite changes seen in oncology that are not prostate-specific are also present in semi-
nal fluid. Disturbed synthesis and intracellular depletion of polyamines, such as spermine, are reflected in 
prostatic fluid (Cheng et al., 2001; Kline et al., 2006; Serkova et al., 2008; van der Graaf et al., 2000). 
The prostate contains the highest levels of spermine in the body, and disturbances in ornithine-
decarboxylase in polyamine metabolism have been a hypothesized mechanism for spermine depletion 
(Mohan et al., 1999; Simoneau et al., 2008; van der Graaf et al., 2000). A role of increased reactive oxy-
gen species production by increased expression of spermine oxidase in PCa has linked inflammation with 
PCa carcinogenesis (Goodwin et al., 2008). Levels of myo-inositol, a molecule involved in membrane 
biosynthesis, have also been shown to be reduced in prostatic fluid (Lynch & Nicholson, 1997; Serkova 
et al., 2008). 
Some changes in metabolite levels in prostatic tissue are not reflected in prostatic fluid. Choline is 
upregulated in PCa tissue, both in vitro and in vivo, being hypothesized as another metabolite involved in 
membrane biosynthesis. The use of choline as a marker in prostatic fluid is compromised by the endoge-
 nous conversion of phosphocholine (from the seminal vesicles) to choline catalyzed by prostatic acid 
phosphatase (from the prostate) shortly following ejaculation. This produces a biological artefact in cho-
line concentration.  Lactate and alanine are also increased in PCa tissue as part of the Warburg effect. 
However, spermatozoa utilize fructose from the seminal vesicles and glucose via glycolysis to produce 
ATP to fuel flagellal movement in utero to aid fertilization, resulting in varying levels of lactate and ala-
nine as metabolic by-products. This illustrates a confounding factor between external cellular compo-
nents and intraprostatic metabolites. 
 
PCa-induced 
change 
Metabolite Role (normal) Alteration  
hypothesis 
Reference 
Increase Choline Membrane phospholipid 
precursor 
Increased  
membraneogenesis 
(DeFeo & Cheng, 2010; 
Swanson et al., 2003, 2006, 
2008) 
Lactate End product of anaerobic 
glycolysis 
Warburg effect (DeFeo & Cheng, 2010; 
Swanson et al., 2006; Tessem et 
al., 2008) 
Alanine End product of anaerobic 
glycolysis 
Warburg effect (DeFeo & Cheng, 2010; 
Swanson et al., 2006; Tessem et 
al., 2008) 
Omega-6  
fatty acids 
Cell membrane biosyn-
thesis, fatty acid oxida-
tion 
Altered gene  
Expression 
(Stenman et al., 2009) 
Cholesterol Membrane biosynthesis,  
androgen regulated 
Increased cell  
Turnover 
(Thysell et al., 2010) 
Sarcosine Glycine metabolism, 
purine synthesis 
Cell invasion (Sreekumar et al., 2009) 
(Choline + crea-
tine) / citrate 
Metabolite ratio Increased ratio (Kurhanewicz et al., 1995; van 
Asten et al., 2008) 
Choline / citrate Metabolite ratio Increased ratio (van Asten et al., 2008) 
Choline / crea-
tine 
Metabolite ratio Increased ratio (van Asten et al., 2008) 
Decrease Citrate Ion homeostasis,  
pH buffer 
m-aconitase  
activation 
(Serkova et al., 2008) 
Spermine Polyamine synthesis Oxidative stress, enzyme 
alteration 
(Serkova et al., 2008; van der 
Graaf et al., 2000) 
Myo-inositol Membrane biosynthesis  (Serkova et al., 2008) 
Citrate / sperm-
ine 
Metabolite ratio Decreased ratio (Lynch & Nicholson, 1997) 
Citrate / creatine Metabolite ratio Decreased ratio (van Asten et al., 2008) 
Table 3: Summary of metabolite changes in prostate cancer. Changes generic to cancer, such 
as lactate and alanine, are listed together with changes specific to prostate physiology, such as 
citrate, sarcosine and spermine. Adapted from (Roberts et al., 2011). 
3.3    Metabolomics in Prostate Cancer Diagnosis: Finding the Best Combination 
Metabolite concentrations and ratios have aided in distinguishing PCa from benign prostates (Swanson et 
al., 2003, 2008; Tessem et al., 2008; van Asten et al., 2008). Yet, despite promising preliminary results, 
 there is currently no test available that is accepted as an accurate, stand-alone diagnostic or screening test. 
With improved data acquisition and processing technology, the concept of using entire metabolic profiles 
as a large-scale combination of biomarkers has become feasible. Furthermore, metabolite profiles have 
been shown to be more sensitive as predictors of PCa, and in predicting metastatic potential (Hricak et 
al., 2007) (Cheng et al., 2005; Mazaheri et al., 2008; Wu et al., 2010). This concept has been demon-
strated by metabolomic imaging, in which multivoxel MR spectra of intact prostates were analysed with 
MVSA. This was able to detect highly significant changes between the global metabolite profiles of be-
nign and malignant prostate tissue without the need to identify specific metabolites (Wu et al., 2010). 
Similar relationships were demonstrated using freshly frozen PCa tissue when microarray gene expres-
sion data and metabolomic data were combined using PLS, providing further insight into mechanisms of 
metabolite alterations in PCa (Bertilsson et al., 2012). In another study, metabolomic profiling provided 
an accurate prediction of biochemical recurrence of PCa, that is a rise in serum PSA, following interven-
tion (Maxeiner et al., 2010). This illustrates the potential of metabolomics as a suitable method for moni-
toring PCa behavior following clinical interventions (Roberts et al., 2011). 
The concept of multiple markers in cancer diagnosis has been examined for some time. Specific to 
PCa, panels of molecular and protein-based markers have been used to improve serum PSA-based PCa 
detection (Cao et al., 2011; Cuperlovic-Culf et al., 2010; Talesa et al., 2009). The most widely publicized 
and promising appear to be the combination of PCA3 and TMPRSS2-ERG fusion transcripts in post-
massage urine as previously described. Multiple studies have shown improved sensitivity when combin-
ing PCA3 and TMPRSS2-ERG compared with PCA3 or serum PSA alone (Hessels et al., 2003; Tomlins 
et al., 2011). Multiple mRNA markers (GalNAc-T3, PSMA, Hepsin and PCA3) in malignant prostate 
tissue have been able to provide optimal detection rates (Clarke et al., 2010; Landers et al., 2005, 2008). 
Other researchers have attempted to combine single markers of different origins to improve PCa diagno-
sis. For example, a multiplex model utilizing gene-, protein- and metabolite-based targets for PCa outper-
formed any single biomarker (Cao et al., 2011). However, although these studies are promising in im-
proving PCa diagnosis, many are impractical for use in a clinical setting, mostly due to financial and lo-
gistical constraints. Thus, in addition to improved accuracy, a further potential benefit of using metabo-
lomics in PCa diagnosis is a reduction in cost and logistical requirements for each sample, although a 
high initial capital equipment financial outlay is required. Further limitations of this approach are out-
lined below. 
3.4    Limiting/Confounding Factors 
As previously discussed, detecting PCa is difficult. This is due to many confounding factors relating to 
the pathophysiology of PCa, but also due to concomitant prostatic disease mimicking PCa. In the majori-
ty of studies to date, the greatest interference arises from concomitant pathophysiology of the prostate, 
such as BPH and prostatitis. Serum PSA is known to be elevated in BPH: androgens contributing to BPH 
development drive PSA synthesis which is mirrored in serum levels. Prostatitis associated with inflam-
mation and prostatic cell lysis, results in increased release of intracellular PSA into the bloodstream, ele-
vating serum PSA. It is for these reasons that serum PSA lacks sensitivity (detecting many false posi-
tives) and that there is sustained criticism directed toward serum PSA testing.  
Tissue and prostatic fluid levels of citrate were reported to be initially promising in PCa diagnosis 
compared with serum PSA, but were observed in the past to be depleted in prostatitis (Averna et al., 
2005; Kavanagh et al., 1982; Kline et al., 2006). Notwithstanding similar potential dilemmas as those 
 experienced with serum PSA, diminished levels of both zinc and citrate in these samples may provide 
improved sensitivity in PCa detection, although conclusive evidence in conjunction with PSA elevations 
is lacking to date (Daragó et al., 2011; Kavanagh et al., 1982; Zaichick et al., 1996). The relationship of 
citrate depletion in tissues following radiotherapy or hormonal therapy also relates to biochemical recur-
rence, defined as a rising serum PSA following intervention with curative intent (Menard et al., 2001; 
Mueller-Lisse et al., 2001). Furthermore, reduced specificity of serum PSA when compared with metabo-
lite diagnosis may be due to pre-malignant disturbances in metabolic homeostasis that are not histologi-
cally visible (Costello & Franklin, 2009). The underlying issue of biochemical characterisation preceding 
histopathology creates ongoing uncertainty, as tissue histopathology is the current gold standard for PCa 
diagnosis. 
Intra- and extracellular citrate levels are also known to increase in BPH, thus citrate estimation in 
biopsy tissue may be unreliable. In these circumstances, prostatic fluid may be a more appropriate sample 
to use since prostatic fluid is produced mostly in the peripheral zone, which is also where most PCa is 
located (Costello & Franklin, 2009), whereas BPH develops in the transition (central) zone of the pros-
tate. A small proportion of transition zone tumors may be missed, but in the large majority of cases these 
are less aggressive and therefore of less significance (Grignon & Sakr, 1994).  
4    Future Directions 
4.1    Pharmacometabolomics and Theranosis: Towards Personalized Medicine 
Pharmacometabolomics seeks to predict the metabolic response to exogenous therapeutic agents prior to 
or during drug administration, and theranosis is the identification and monitoring of optimal treatments 
for patients as guided by diagnostic tests (Clayton et al., 2006; DeNardo & DeNardo, 2012; Nicholson et 
al., 2012). Both are important aspects, given the recently emerging evidence of inter-individual differ-
ences in drug pharmacokinetics, being the ability of an individual to absorb, distribute, metabolize and 
excrete an administered drug (Suhre et al., 2011). The result is reduced therapeutic efficacy, but may also 
be responsible for toxicity and adverse drug effects. The etiology of these differences in drug metabolism 
is diverse and is well understood in only a limited number of circumstances (e. g. Cytochrome p450 en-
zyme family (De Gregori et al., 2010)). Gender, age, race and concomitant diseases have been suggested 
as inherent factors, but have yet to be substantiated (Nebert et al., 2003). External factors such as dietary 
and lifestyle habits, as well as toxin exposure, may also have a large influence on therapeutic efficacy. 
Furthermore, less obvious but important factors may contribute, such as altered gut flora in various cir-
cumstances (Dumas et al., 2006; Ley et al., 2006; Wang et al., 2011). As such, metabolic phenotypes are 
diverse and complex due to these many influencing factors (Holmes et al., 2008). Although genetic pro-
filing across different disorders is important, metabolite profiling promises to better reflect the phenotype 
of disease states, and advanced analysis between both methods may help to identify genes with signifi-
cant penetrance. 
As has been illustrated, the carcinogenic changes in various cancers will cause common changes to 
individual metabolic profiles that can be investigated with metabolomics. In contrast, each individual 
patient will exhibit inherently different metabolic profiles, while also responding differently to therapeu-
tic interventions (Wilson, 2009). Thus, the concept of personalized medicine, where treatments are tai-
lored to an individual’s personal metabolic or genetic phenotype, is one that is exciting, and important in 
 advancing medical treatments (Loscalzo et al., 2007). Using metabolite profiles as a representation of 
metabolic phenotype promises to enable theranosis by providing the most useful information for predict-
ing inter-individual variation that will guide and assess efficacy of treatment outcomes. 
Early research focused on genetic predisposition to cancer or alterations in drug-metabolizing en-
zymes (Yong et al., 2006). Recent research has focused on identifying varying metabolic profiles that 
indicate significantly affected drug metabolism, with links to altered gut flora homeostasis (Clayton et 
al., 2006, 2009). This research related individual background urinary metabolic phenotype to biological 
and therapeutic outcomes of drug metabolism. Other research has identified alterations in metabolite pro-
files to illustrate pharmacokinetics and early toxicity, important in preventing adverse outcomes from 
drug toxicity (Winnike et al., 2010). Recently, this approach has been applied to surgery, and allows for 
personalized pre-, intra- and post-operative care to improve patient outcomes (Kinross et al., 2011; 
Mirnezami et al., 2012). The concept of pharmacometabolomics can also be applied to outcome predic-
tion, similar to that used in GWAS, with evidence of serum metabolite levels to be predictive of body 
mass following chemotherapy for breast cancer (Keun et al., 2009).  
Theoretically, pharmacometabolomics has advantages over pharmacogenomics in representing the 
phenotype resulting from multiple genetic effects. However, it is believed that a combination of ap-
proaches will provide best prediction and outcomes (Nicholson et al., 2011). Given current variations in 
efficacy, toxicity and adverse outcomes of treatments, developing personalized medicine is imperative to 
provide better medical care to patients while also reducing health budget costs. Thus, the pharma-
cometabolomic approach is one that has potential to change the therapeutic landscape not only in oncolo-
gy, but across all fields of medicine. 
4.2    Metabolomics to Elucidate Biological Mechanisms 
As outlined, metabolomics has been useful in displaying changes in metabolites in various healthy and 
pathological states. The analysis of metabolites illustrates the end product of normally functioning or dis-
turbed cellular processes and mechanisms. Thus, analysis of changes in metabolite profiles can lead to 
insights about the underlying biochemical or biological mechanisms. This has been demonstrated in dif-
ferent areas, including but not limited to, drug toxicity, cancer and plant studies (Bylesjö et al., 2007, 
2008; Klenø et al., 2004; Rantalainen et al., 2006).  
For example, metabolomics could explain how altered STAT5 signaling as a result of truncated in-
tracellular domains of growth hormone receptor in liver tissue leads to late-onset obesity, as systemic 
metabolite changes were consistent with globally altered metabolism contributing to obesity (Schirra et 
al., 2008). A similar approach was used for data obtained from a human prostate cancer xenograft model 
in mice measured by NMR-based metabonomics and proteomics (two dimensional difference gel elec-
trophoresis). Pathway analysis was used to link altered protein expression to changes in amino acids, 
which contributed to the metabolic phenotype (Rantalainen et al., 2006). 
4.3    Integration with other –omics  
As previously outlined, the –omics approach to sample analysis provides data sets that require complex 
statistical analysis to extract meaningful information. In isolation, each –omics field provides insight into 
that particular level of cell function, and interactions and influences causing the results are hypothesized 
based on previous research or logical thinking. Thus, appropriate integration of –omics datasets has be-
come an important step in providing meaningful information in systems biology (Crockford et al., 2006; 
 Bylesjö et al., 2008). This approach was e.g. used in insulin resistant mice using NMR-based metabo-
nomics and genomics (quantitative trait locus mapping), and showed altered gut metabolites that were 
linked with genomic alterations (Dumas et al., 2007). In both studies, large datasets were used to deter-
mine which metabolites were similarly affected by alterations in precursor compounds.  
A suggested method that uses O2PLS for integration of large datasets for optimal information re-
covery is outlined in Figure 10 (Bylesjö et al., 2008), using the example of a study that has data from 
transcriptomics, proteomics and metabolomics experiments. As O2PLS is able to extract information 
from two datasets at a time, the method for correlating multiple datasets is naturally a multi-step proce-
dure. In the first step the joint variation between two of the three datasets (e.g. transcript and metabolite 
data) is extracted by O2PLS. This means using one of the datasets as X matrix in O2PLS and the other 
one as Y matrix. Note that in this case, O2PLS is effectively run as unsupervised analysis, because only 
two experimental datasets are correlated against each other, without including a set of external metadata. 
In the second step, the joint variation between transcript and metabolite data obtained in step 1 is then 
correlated with the third dataset (proteomics) in a second O2PLS, which will yield the variation common 
to all three datasets. In the final step, the joint variation that is common to all three datasets is deflated 
from the original datasets in a series of three parallel O2PLS analyses, to produce variation that is specif-
ic to each dataset.  
It is trivial to extend this scheme to more than three datasets by adding on further O2PLS steps be-
tween steps 2 and 3 that each time introduce a further set of experimental data into the analysis. It should 
also be noted that it is prudent to repeat the first two steps with different orders of combining the three 
datasets – e.g. transcript and metabolite data first, then including protein data, versus metabolite and pro-
tein data first, then including transcript data, etc. – in order to rule out that potential slight imperfections 
in the symmetry behavior of O2PLS might cause secondary effects on the data analysis.   
 
Figure 10: Graphic representation of stepwise data integration of multiple –omics datasets 
with O2PLS. In the first step, joint variation between two –omics datasets (e.g. transcript and 
metabolite data) is determined. Using O2PLS in a second step, this joint variation is then cor-
related with the third –omics dataset (e.g. protein data) to determine variation that is joint to all 
three sets of data. The third step removes the joint variation between all three individual da-
tasets to produce variation that is specific to each dataset. This dataset-specific variation may 
be important in helping to address the biological question. Adapted from (Bylesjö et al., 2008). 
  
4.4    Use of Computational Modeling 
As is widely highlighted, the current approach to metabolomics including valid statistical analysis, me-
tabolite identification, and biological interpretation is highly time-consuming. As such, the quest to de-
velop computerized methods of metabolite analysis and identification is underway (Aggio et al., 2011; 
Tulpan et al., 2011). Following metabolite identification, the next step is to determine the relationship 
and similarities, if any, of the identified metabolites to metabolic pathways, of which some preliminary 
programming applications have been released to address this issue (Aggio et al., 2010; Bebek & Yang, 
2007; Leader et al., 2011). 
Even more promising is the development of genome-scale computer models of metabolic net-
works. Extensive work has been completed on bacteria such as Escherichia coli, with in silico simulation 
reported to mimic experimental changes (Edwards et al., 2001). Application of these reconstructed net-
works is more complicated in eukaryotes, such as human cells, due to the complex cellular and organis-
mic organisation, including intra- and extra-cellular regulation and interactions. Despite these, an initial 
model human cell was constructed to provide a general baseline in expression and response to biological 
variables (Bordbar & Palsson, 2012; Mo et al., 2007). Furthermore, a reconstruction of healthy liver cells 
was combined with whole-body pharmacokinetics to investigate multiple levels in biological organisa-
tion and provide mechanistic insights into for various drug-induced scenarios (Krauss et al., 2012). Al-
terations to such models to accurately reflect cancer and other pathophysiological states by incorporating 
known and emerging evidence will better describe the response of these cells (Jerby & Ruppin, 2012).  
Depending on the type of model, spatiotemporal processes and interactions within cells that may be un-
definable or difficult to quantify are currently difficult to incorporate and apply to an artificial model 
(Materi & Wishart, 2007). Further development of these reconstructed networks may occur via integra-
tion of –omics data sets, and research in this field is continuing (Joyce & Palsson, 2006). Computational 
modeling by incorporating multiple data sets represents a logical and informative, yet challenging, ap-
proach to oncology research to guide pharmaceutical development strategies. The result will be better 
informed treatment approaches and improved treatment outcomes for these patients.  
5    Conclusions 
Metabolomics is a novel, modern and robust scientific approach that has shown great advances across 
many fields in biomedical research. The application of metabolomics to differing fields in medical sci-
ence, including pathophysiology insight, drug development and in vivo imaging make it unique from all 
other approaches. Further research and collaboration to develop reconstructed networks, via integration 
of many terabytes of –omics data, is the next frontier in providing valuable insights to advance medical 
research and treatments in various human disease states. 
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